Work

Safety and Tolerability of Cael-101, an Anti-amyloid Monoclonal Antibody, in Combination With Plasma Cell Dyscrasia Therapy in Patients With Light-chain Amyloidosis: Results From a Phase 2 Study

Year: 2022

Type: article

Source: Journal of the American College of Cardiology

DOI: 10.1016/s0735-1097(22)01296-7

Authors: Jason Valent, Michaela Liedtke, Jeffrey Zonder, John Silowsky, Michael Kurman, Eileen Daniel, Janet Jobes, Mark Harnett, Amit Bhattacharyya, Candida Cristina Quarta, Julia Catini, Jessica Raviwong, Michael Spector, Susan Sobolov

Institution: Alexion Pharmaceuticals (United States)

Language: English

Topic: Amyloidosis: Diagnosis, Treatment, Outcomes

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4220768424

FWCI: 0.276

Cites:

Cited by: 5

Related to: 10